-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
BRCA1 and BRCA2 play a central role in DNA repair.
, patients with the embryo line (g) BRCA1/2 mutation (m) may have a higher risk of developing blood toxicity after chemotherapy treatment.
this study analyzed two breast group studies of early triple-negative breast cancer (TNBC) patients with known gBRCA1/2 mutation status and receiving new complementary chemotherapy treatment for cyclocycline.
the primary goal is the reduction rate of class III-IV (G) neutral granulocytes during the first course (C1).
secondary objectives include the effects of C1 on population and other GIII-IV hematological toxicity, as well as cumulative hemotoxicity throughout the cycle, relative total dose strength, and prevention of granulocyte concentration stimulation factors.
the blood toxicity of yewane, carbaptonin and cyclophosphamide were discussed.
209 (17.8%) of the 1,171 subjects who had the effect of the gBRCA1/2 mutation on the occurrence of blood toxicity carried the gBRCA1/2 mutation.
C1, 37.4% of gBRCA1/2 mutant patients had GIII-IV neutral granulocyte reduction, while 35.7% of wild patients had GIII-IV neutral granulocytosis (P-0.683).
in the multivariable regression model, for C1, gBRCA1/2m can neither predict GIII-IV neutral granulocyte reduction (advantage ratio of 1.26, 95% CI 0.87-1.1.) 82, P.0.226), and no other GIII-IV hematotoxic toxicity (OR 0.91, 95% CI 0.64-1.31, P=0.0.625).
similar results from cumulative toxicity analysis of the entire cycle, except for GIII-IV plate small plate reduction (increased in gBRCAm patients).
the effects of
gBRCA1/2 mutations on blood toxicity in different drug treatment patients treated with yew alcohol, the risk of GIII-IV blood toxicity in gBRCA1/2m patients was higher than in wild type (59.5% vs 43.1% ;P-lt;0.001).
did not differ in patients with cyclophosphamide or platinum-containing chemotherapy.
under standard chemotherapy, TNBC patients with gBRCA1/2 mutations did not have a high risk of developing severe blood toxicity during the first course of treatment or throughout the treatment cycle.
in patients with gBRCA1/2 mutations may have a higher risk of developing GIII-IV blood toxicity under yew alcohol therapy and require further study.
